Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
7Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Arvinas, Inc. (ARVN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
4Distinct source URLs
9High confidence
0.813Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commerc…
Reciprocal relationship from PFE graph: Reciprocal relationship from ARVN graph: In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of …
Reciprocal relationship from PFE graph: Reciprocal relationship from ARVN graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ARVN graph: Revenue for the quarter is related to…
Revenue for the quarter is related to the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer and the collaboration and license agreement with Pfizer.
RIGEL-PHARMACEUTICALS-INC
RIGEL-PHARMACEUTICALS-INC
85%
Entered into a license agreement with Rigel Pharmaceuticals, Inc. for the for the exclusive global development, manufacturing, and commercialization rights for VEPPANU.
BAYER-AG
BAYER-AG
62%
ch 31, 2026 and 2025, respectively. Other Income Other income totaled $6.3 million for the three months ended March 31, 2026, compared to $11.7 million for the three months ended March 31, 2025. The …
NVS
Novartis AG
62%
Reciprocal relationship from NVS graph: Reciprocal relationship from ARVN graph: Reciprocal relationship from NVS graph: Reciprocal relationship from ARVN graph: Reciprocal relationship from NVS grap…
PHARMA-AG
PHARMA-AG
62%
. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into the second half of 2028, which will enable us to execute on multiple …
VEPPANU-PFIZER-RESEARCH-CO
VEPPANU-PFIZER-RESEARCH-CO
62%
. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into the second half of 2028, which will enable us to execute on multiple …
Arvinas, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ARVN-DEBT-7862
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2023-12-31.
ARVN-DEBT
Debt stack $500,000
90%
Market cache reports total debt of $500,000.
ARVN-DEBT-7863
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
Arvinas, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Arvinas, Inc..
Arvinas, Inc. Ownership
Holder
Name
Confidence
Evidence
ARVN-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 208 tracked holders.
